In Vivo Patient Preoperative Skin Prep Persistence

NCT ID: NCT02447497

Last Updated: 2024-10-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to demonstrate persistence of the CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to demonstrate persistence of the CHG/IPA Prep versus a saline placebo on skin flora of the abdominal and inguinal regions of human subjects as measured by change in microbial flora relative to baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Recovery of Skin Flora Post-Product Application

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3M CHG/IPA - Abdominal Region

Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.

Group Type EXPERIMENTAL

3M CHG/IPA Surgical Skin Preparation - Abdominal Region

Intervention Type DRUG

Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Normal Saline - Abdominal Region

Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.

Group Type PLACEBO_COMPARATOR

Normal Saline - Abdominal Region

Intervention Type OTHER

0.9% sodium chloride applied with foam applicator

3M CHG/IPA - Inguinal Region

Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.

Group Type EXPERIMENTAL

3M CHG/IPA Surgical Skin Preparation - Inguinal Region

Intervention Type DRUG

Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Normal Saline - Inguinal Region

Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.

Group Type PLACEBO_COMPARATOR

Normal Saline - Inguinal Region

Intervention Type OTHER

0.9% sodium chloride applied with foam applicator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3M CHG/IPA Surgical Skin Preparation - Abdominal Region

Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Intervention Type DRUG

Normal Saline - Abdominal Region

0.9% sodium chloride applied with foam applicator

Intervention Type OTHER

3M CHG/IPA Surgical Skin Preparation - Inguinal Region

Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Intervention Type DRUG

Normal Saline - Inguinal Region

0.9% sodium chloride applied with foam applicator

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SoluPrep SoluPrep

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of any race
* Subjects in good general health
* Minimum skin flora baseline requirements on abdomen and groin

Exclusion Criteria

* Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test areas
* Topical antimicrobial exposure within 14 days prior to screening and treatment days
* Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

3M

INDUSTRY

Sponsor Role collaborator

Solventum US LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhammad H Bashir, MD, CCRP

Role: PRINCIPAL_INVESTIGATOR

MicroBioTest Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MicroBioTest

Sterling, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EM-05-013509

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preoperative Skin Preparation Evaluation
NCT00636480 COMPLETED PHASE3
Povidone-Iodine for Nasal Decolonization
NCT05529173 COMPLETED PHASE4
Single Dose CHG Pharmacokinetic Study
NCT03331263 COMPLETED PHASE1